grade
pharmaceutical primary standard
API family
estradiol
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
SMILES string
CCCCC(=O)OC1CCC2C3CCc4cc(O)ccc4C3CCC12C
InChI
1S/C23H32O3/c1-3-4-5-22(25)26-21-11-10-20-19-8-6-15-14-16(24)7-9-17(15)18(19)12-13-23(20,21)2/h7,9,14,18-21,24H,3-6,8,10-13H2,1-2H3
InChI key
RSEPBGGWRJCQGY-UHFFFAOYSA-N
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Estradiol valerate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
Still not finding the right product?
Explore all of our products under β-雌二醇 17-戊酸酯
signalword
Warning
hcodes
Hazard Classifications
Aquatic Chronic 1 - Carc. 2 - Lact. - Repr. 2
存储类别
11 - Combustible Solids
wgk
WGK 3
法规信息
涉药品监管产品
此项目有
C Egarter et al.
Acta obstetricia et gynecologica Scandinavica, 75(4), 386-393 (1996-04-01)
Two sequential hormone replacement regimens, containing either estradiol valerate plus medroxyprogesterone acetate (E2V/MPA) or conjugated estrogens plus medrogestone (CE/MED), were compared with respect to effects on climacteric symptoms, lipid metabolism, and hemostasis. In an open, multicenter study, 51 perimenopausal women
Sheridan M Hoy et al.
Drugs, 69(12), 1635-1646 (2009-08-15)
Estradiol valerate/dienogest is an oral contraceptive for women that combines the natural estrogen estradiol with the 19-nortestosterone derivative dienogest in a four-phasic formulation. Estradiol valerate/dienogest demonstrated contraceptive efficacy in a large (n = 1377), noncomparative, multicentre study in women aged
Clinical efficacy and safety of combined estradiol valerate and dienogest: a new no-bleed treatment.
B von Schoultz
Climacteric : the journal of the International Menopause Society, 6 Suppl 2, 24-32 (2003-12-13)
A combination of 2 mg estradiol valerate with 2 mg dienogest (E2V/DNG) (Climodien, Schering AG, Berlin, Gemany) is the first continuous combined postmenopausal hormone replacement therapy (HRT) preparation to contain a progestogen with substantial antiandrogenic activity. A study of its
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| Y0000046 | 04061833801857 |